Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
Atherosclerosis（2018）
摘要
Image 1
更多查看译文
关键词
Alirocumab,Cardiovascular disease,Low-density lipoprotein cholesterol,Lipid-lowering therapy,Open-label extension,PCSK9
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要